Lysergide for Attention deficit hyperactivity disorder

Inclusion criteria

• {"criterion_text":"- Ability and willingness to provide written, informed consent prior to initiation of any study-related procedures and to adhere to all study requirements."}
• {"criterion_text":"- Participants experience symptoms that meet the DSM-5 criteria for ADHD, as determined by clinical evaluation and confirmed by a structured interview (SCID-5). Participants may experience ADHD symptoms with or without comorbid disorders, including, but not limited to, emotion and sleep disorders."}
• {"criterion_text":"- ASRS total score ≥ 14 at screening."}
• {"criterion_text":"- Free from psychotropic medication, including ADHD medication."}
• {"criterion_text":"- Must be willing to refrain from taking illicit psychoactive substances during the study."}
• {"criterion_text":"- Must be willing to receive the study medication once every third day for 6 weeks. During three lab visits (P1, L1, L8) participants must be willing to take a taxi or public transportation home or be accompanied by a caregiver and not drive a vehicle home. During at-home administration days, participants must be willing to not drive a vehicle or use heavy equipment for 6 hours after administering the study medication."}
• {"criterion_text":"- Must be willing to refrain from any alcoholic drinks during the weekdays (Monday to Friday, inclusive). During the weekend, must be willing to refrain from more than 6 standard alcoholic drinks per week (1 standard drink corresponds to 0.1 L wine, 0.3 L beer, or 4 cL liquor)."}
• {"criterion_text":"- Must be willing to refrain from more than 10 cigarettes a day, and more than 2 cups of coffee a day throughout the study treatment period (6 weeks) and until the last study visit is complete (EOS)."}
• {"criterion_text":"- Understanding the procedures and the risks associated with the study"}
• {"criterion_text":"- Age between 18 and 50 years old at screening"}
• {"criterion_text":"- Normal weight, body mass index (weight/height2) between 18 and 28 kg/m2"}

Exclusion criteria

• {"criterion_text":"- Past or present diagnosis of a primary psychotic disorder, including bipolar I or II disorder (DSM-V), or first-degree relative with a psychotic disorder"}
• {"criterion_text":"- History of cardiac dysfunctions (arrhythmia, ischemic heart disease, etc.)"}
• {"criterion_text":"- Any lifetime history of suicide attempt, ideation or behavior; or current (within past week prior to the screening visit) active suicidal thoughts or ideation; (as determined by positive answers on sSuicidality-related questions on the SCID-5-SV)."}
• {"criterion_text":"- Planning to start, stop, or alter the use of any medications, supplements, or other therapeutics from the time of providing informed consent until EOS"}
• {"criterion_text":"- Likely to require psychiatric hospitalisation during the course of the study"}
• {"criterion_text":"- Likely to need use of any psychiatric medications with the potential to confound interpretation of study results or impact safety, at the discretion of the Investigator, in the 6 weeks following Baseline up to EOS"}
• {"criterion_text":"- Not willing or able to stop psychotropic medication (e.g., SSRIs, ADHD medication, etc.) prior to the baseline visit through EOS."}
• {"criterion_text":"- Use of weight loss drugs within 21 days of screening until the end of study."}
• {"criterion_text":"- Planning to start, stop or alter the use of psychotherapy, massage, meditation, acupuncture, hypnosis, yoga, or other similar therapy/activity from the time of providing informed consent until EOS"}
• {"criterion_text":"- Use of potent CYP2D6 inhibitors; moderate CYP2D6 inhibitors by Investigator discretion"}
• {"criterion_text":"- Experience with a psychedelic drug (psilocybin, LSD, mescaline, Ayahuasca, DMT, 5-MeO-DMT) within the last 6 months prior to the screening visit"}
• {"criterion_text":"- Previous experience of serious side effects to psychedelic drugs (anxiety or panic attacks)"}
• {"criterion_text":"- Participants with a positive urine drug screen at screening OR any of the lab visits"}
• {"criterion_text":"- Any clinically significant abnormal electrocardiogram (ECG) finding (e.g., uncontrolled atrial fibrillation, ischemia) at screening, as determined by the medical supervisor (in consultation with a cardiologist, if needed)."}
• {"criterion_text":"- Any other condition, therapy, laboratory abnormality, or other circumstance that, in the opinion of the medical supervisor, may pose additional risk to the subject from participation in the study, may interfere with the subject’s ability to comply with study procedures, may make participation in the study not in the subject’s best interest or may confound the results of the study."}
• {"criterion_text":"- Not willing or not able to consume alcohol in any amount (including due to religious or personal reasons), since the study medication will be dissolved in a small quantity (1 ml) of 95% Vol. ethanol."}
• {"criterion_text":"- Past (>12 months prior to the screening visit) or present substance addiction or dependence (determined by positive answers on the substance abuse questions in the SCID-5-SV, and the drug and alcohol consumption questions in the MDQ) except nicotine, provided consumption does not exceed (the equivalent of) 10 cigarettes per day."}
• {"criterion_text":"- Women of childbearing potential (WOCBP) (i.e., physiologically capable of becoming pregnant) who are unwilling or unable to use a highly effective method of contraception for the duration of the study, OR Men physiologically capable of fathering a child who are sexually active with WOCBP but are unwilling or unable to use barrier contraception (e.g., condom with or without spermicidal cream or jelly) for the duration of the study."}
• {"criterion_text":"- Women who are currently pregnant or lactating or plan to become pregnant or breastfeed during the study."}
• {"criterion_text":"- Men who plan to donate sperm during the study."}
• {"criterion_text":"- Somatic disorders including Central Nervous System (CNS) involvement of cancer, severe cardiovascular disease, untreated hypertension, severe liver disease, severely impaired renal function, or anything else that, in the judgement of the medical supervisor, poses too great a potential for side effects."}
• {"criterion_text":"- Hypertension (diastolic > 90 mmHg; systolic > 140 mmHg)"}

Primary endpoints

• {"endpoint_text":"- ADHD symptoms","definition_or_measurement_approach":"Measured as core ADHD symptom change; associated patient-facing documents include Adult ADHD Investigator Symptom Rating Scale (AISRS) and ASRS screening criteria."}
• {"endpoint_text":"- Emotion regulation","definition_or_measurement_approach":"Measured as change in emotion regulation; associated patient-facing document includes Emotion regulation visual analogue scale (ER-VAS)."}
• {"endpoint_text":"- Sleep","definition_or_measurement_approach":"Measured as sleep outcome changes (details in protocol patient-facing documents); specific sleep assessment instruments not detailed in the available JSON."}

Secondary endpoints

• {"endpoint_text":"- Pharmacokinetic profile","definition_or_measurement_approach":"Pharmacokinetic (PK) profiling of the investigational agent (PK sampling and analysis as described in secondary objectives)."}
• {"endpoint_text":"- Theta-beta power ratio","definition_or_measurement_approach":"EEG-derived theta-beta power ratio (TBR) measurement as indicated in secondary objectives (brain oscillations)."}
• {"endpoint_text":"- CYP2D6 functionality","definition_or_measurement_approach":"Assessment of CYP2D6 functionality/genetic profile (CYP) as a secondary endpoint per objectives."}
• {"endpoint_text":"- Polygenic risk score","definition_or_measurement_approach":"Calculation of polygenic risk score (PRS) from genetic data as described in secondary objectives."}

Netherlands

Earliest CTIS Part Ii Submission Date

09-04-2026

Latest Decision Or Authorization Date

11-05-2026

Processing Time Days

32

Number Of Sites

1

Number Of Participants

120

Primary sponsor

Full Name

Universiteit Maastricht

Organisation Type

Educational Institution

Country Of Registered Address

Netherlands

Third parties

• {"country":"Germany","full_name":"Universitaetsklinikum Bonn AöR","duties_or_roles":"code:4","organisation_type":"Hospital/Clinic/Other health care facility"}
• {"country":"Netherlands","full_name":"Zwiers Regulatory Consultancy B.V.","duties_or_roles":"code:8","organisation_type":"Pharmaceutical company"}
• {"country":"Germany","full_name":"MVZ Dr. Stein + Kollegen SE & Co. eGbR","duties_or_roles":"code:4","organisation_type":"Hospital/Clinic/Other health care facility"}
• {"country":"Switzerland","full_name":"Apotheke Dr. Hysek AG","duties_or_roles":"code:14","organisation_type":"Pharmaceutical company"}
• {"country":"Switzerland","full_name":"Lipomed AG","duties_or_roles":"code:14","organisation_type":"Pharmaceutical company"}
• {"country":"Netherlands","full_name":"Radboud universitair medisch centrum Stichting","duties_or_roles":"code:4","organisation_type":"Hospital/Clinic/Other health care facility"}
• {"country":"Switzerland","full_name":"Universitaetsspital Basel","duties_or_roles":"code:4","organisation_type":"Hospital/Clinic/Other health care facility"}